Results 191 to 200 of about 18,854,124 (268)

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background & Aims The management of comorbidities has become increasingly relevant in unresectable hepatocellular carcinoma (uHCC) as immunotherapy prolongs survival. Atezolizumab plus bevacizumab (AB) is a standard first‐line option, but bevacizumab carries a risk of cardiovascular toxicities.
Bernardo Stefanini   +55 more
wiley   +1 more source

Blood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background and Aims The applicability of non‐invasive tests (NITs) for clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC) is controversial. We performed a head‐to‐head comparison of various NITs for CSPH and evaluated rule‐in/‐out criteria.
Lorenz Balcar   +16 more
wiley   +1 more source

Clinical Impact of Haemophagocytic Lymphohistiocytosis Among Patients With HIV/AIDS and Disseminated Histoplasmosis in a Hyperendemic Region of Northeastern Brazil

open access: yesMycoses, Volume 69, Issue 11, November 2026.
ABSTRACT Background Haemophagocytic lymphohistiocytosis (HLH) is a life‐threatening hyperinflammatory syndrome that may occur in people living with HIV/AIDS (PLWHA), often triggered by opportunistic infections such as disseminated histoplasmosis (DH).
Matheus Alves de Lima Mota   +9 more
wiley   +1 more source

A Case of Drug-Induced Liver Injury Associated With Saw Palmetto. [PDF]

open access: yesCureus
Jayasree Rajendran R   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy